SMART Use of Medication for the Treatment of Adolescent Severe Obesity

Adolescent Obesity Clinical Trial

— SMART  

Official title:

SMART Use of Medication for the Treatment of Adolescent Severe Obesity

Clinical Trial Details — Status: Active, not recruiting

Administrative data

• NCT number: NCT04007393
• Other study ID #: PEDS-2019-26512
• Secondary ID: 1R01DK119456
• Status: Active, not recruiting
• Phase: Phase 2
• Start date: November 21, 2019
• Est. completion date: August 31, 2025

Study information

• Verified date: May 2024
• Source: University of Minnesota
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This study will examine the timing and sequence of using adjunct obesity pharmacotherapy for adolescents with severe obesity who do not respond to lifestyle modification therapy alone.

Description:

This project is studying the best time to add weight loss medication to diet and exercise for helping adolescents who carry extra weight. All participants start with a lifestyle modification program and some participants may also receive study medication.Participants must be 12-17 years of age and carry extra weight. The program will last for 48 weeks.

Recruitment information / eligibility

• Status: Active, not recruiting
• Enrollment: 150
• Est. completion date: August 31, 2025
• Est. primary completion date: August 31, 2024
• Accepts healthy volunteers: No
• Gender: All
• Age group: 12 Years to 17 Years

Eligibility

Inclusion Criteria:

• Provision of signed and dated informed assent form;

• Provision of signed and dated informed parental consent form from at least 1 legal parent/guardian;

• Stated willingness to comply with all study procedures and availability for the duration of the study;

• BMI >/= 1.2 times the 95th percentile or BMI >/= 35 Kg/m2, whichever is lower;

• Tanner stage >/= 2;

• Male or female, aged 12-17 at time of consenting;

• For females of reproductive potential: when sexually active, agreement to use highly effective contraception (oral contraceptive pill, intra-uterine device (IUD), or implant) during study participation;

• For males of reproductive potential: use of condoms or other methods to ensure effective contraception with partner.

Exclusion Criteria:

• Contraindications to phentermine or topiramate use according to package inserts, including: history of glaucoma; current or recent (< 14 days) use of monoamine oxidase inhibitor; known hypersensitivity to sympathomimetic amines; current pregnancy, plans to become pregnant, or if sexually active refusal to use 2 forms of birth control; history of cardiac disease including coronary artery disease; clinically significant cardiac arrhythmias; heart failure or uncontrolled hypertension;

• Diabetes (type 1 or 2);

• Presence of cardiac pacemaker;

• Current or recent (<6 months prior to enrollment) use of weight loss medication(s);

• Current use of weight-altering medication(s) (e.g., atypical antipsychotic, metformin) unless dose has been stable for past 6 months;

• Current use of other sympathomimetic amine such as attention-deficit hyperactivity disorder (ADHD) stimulants;

• Seizure disorder (other than infantile febrile seizure);

• Previous bariatric surgery;

• Recent initiation of change in dose (< 3 months prior to enrollment) of anti-hypertensive or lipid medication(s);

• Tobacco use

• History of or current diagnosis of schizophrenia, psychosis, mania, chemical dependency;

• Unstable depression or anxiety that has required hospitalization in the past year;

• Any history of suicide attempt;

• Suicidal ideation or self-harm within 12 months prior to enrollment;

• Bicarbonate < 18 mmol/L;

• Creatinine > 1.2 mg/dL;

• History of cholelithiasis;

• History of nephrolithiasis;

• Untreated thyroid disorder;

• Hyperthyroidism;

• Breastfeeding

Related Conditions & MeSH terms

• Adolescent Obesity
• Obesity
• Obesity, Morbid
• Pediatric Obesity

Intervention

Behavioral:
• Lifestyle Modification Therapy (LSMT)
LSMT will consist of both in-person and by telephone sessions delivered throughout the entirety of the 48-week intervention phase. Each session will last 30-60 minutes. A trained study coordinator (a registered dietician or someone trained by our registered dietician) will delivery this therapy which consists of counseling using education, goal setting and barrier reduction. Topics covered will include calories, tracking, healthy food choices, reducing high fat, added sugar foods, setting goals and portions, changing the quality of your diet, volumetrics, purposeful activity, quick and easy meals, problem solving, food cues and eating patterns, emotional eating, accurate tracking, eating away from home, unhelpful thoughts, structured menus and the role of protein, social cues, managing stress, slips and relapse prevention, long-term physical activity and overcoming obstacles, high-risk situation and keys to success, motivation and looking to the future (long-term plans).

Drug:
• Phentermine Pill
Phentermine will be started only if a participant does not lose 5% of BMI after 12 or 24 weeks of LSMT depending on their random assignment. Subjects will take 15 mg of phentermine every morning for 12 weeks at which time there will be an assessment of weight loss. Subjects who achieve 5% or more BMI reduction after 12 weeks of phentermine will continue 15 mg every morning for the remainder of the study (through week 48) along with their LSMT.
• Topiramate Pill
Participants who do no not achieve at least 5% BMI reduction after 12 weeks of phentermine+LSMT will be re-randomized 1:1 to either topiramate+phentermine+LSMT or topiramate+placebo+LSMT. Topiramate dosing will begin at 50 mg every morning for the first 7 days, and then increase to 100 mg every morning through week 48. At the end of week 48 the taper off will be 50 mg every morning for 7 days and then discontinue.

Locations

Country	Name	City	State
United States	University of Minnesota	Minneapolis	Minnesota

Sponsors (2)

Lead Sponsor	Collaborator
University of Minnesota	National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Percent change in body mass index (BMI)	Body mass index is a measure of body fat based on height and weight.	Baseline, 12-, 24-, 36-, and 48 weeks